,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AC007325.2,,ENSG00000277196,,Unmapped,138082-161852,Predicted intracellular proteins,Evidence at transcript level,HPA020361,Uncertain,,,,,,Tissue enhanced,,skin: 38.5;small intestine: 37.1,duodenum: 29.0,Cell line enriched,7.0,RPTEC TERT1: 137.9
1,ACPT,,ENSG00000142513,"Acid phosphatase, testicular",19,50790415-50795224,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 1.4;testis: 2.2,parathyroid gland: 0.5,Cell line enhanced,,HEK93: 1.3;U-266/84: 1.3
2,ACSBG1,"BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352",ENSG00000103740,Acyl-CoA synthetase bubblegum family member 1,15,78167468-78245688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA041642, CAB045955, HPA058869",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.6;skin: 13.3,adrenal gland: 8.1,Cell line enhanced,,NTERA-2: 3.3
3,ADGRF2,"GPR111, hGPCR35, PGR20",ENSG00000164393,Adhesion G protein-coupled receptor F2,6,47656436-47697797,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA035507,Uncertain,,,,,Not detected,Tissue enhanced,,fallopian tube: 1.5;skin: 1.4,esophagus: 0.3,Not detected,,
4,AIM1L,"CRYBG2, FLJ38020",ENSG00000176092,Absent in melanoma 1-like,1,26321859-26360052,Predicted intracellular proteins,Evidence at protein level,"HPA029629, HPA029631",Uncertain,,Approved,Nucleoplasm,"Endometrial cancer:5.11e-6 (unfavourable), Pancreatic cancer:3.53e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 51.2;skin: 21.5,placenta: 13.7,Cell line enhanced,,BEWO: 33.9;CACO-2: 36.7;CAPAN-2: 27.8
5,AJUBA,"JUB, MGC15563",ENSG00000129474,Ajuba LIM protein,14,22971174-22982642,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA006171,Approved,,Approved,Nucleus<br>Golgi apparatus,Pancreatic cancer:5.67e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 73.7,placenta: 28.0,Mixed,,
6,AL513523.2,,ENSG00000279767,,1,153772371-153774079,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,lymph node: 1.4;skin: 3.5,"cerebral cortex,lung: 0.8",Cell line enhanced,,MCF7: 7.6;SK-BR-3: 5.9;THP-1: 5.5
7,ALS2CL,"DKFZp686I0110, FLJ36525, RN49018",ENSG00000178038,ALS2 C-terminal like,3,46668997-46693704,Predicted intracellular proteins,Evidence at protein level,"CAB046465, HPA048301",Uncertain,,,,Endometrial cancer:8.10e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 38.8,esophagus: 15.8,Cell line enhanced,,CAPAN-2: 30.1;HaCaT: 16.9;HBEC3-KT: 25.9;hTCEpi: 18.1;RT4: 15.4
8,ANKK1,X-kinase,ENSG00000170209,Ankyrin repeat and kinase domain containing 1,11,113387791-113400418,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA012813,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 4.2,fallopian tube: 1.3,Cell line enhanced,,hTCEpi: 1.5
9,ANKRD22,MGC22805,ENSG00000152766,Ankyrin repeat domain 22,10,88822132-88851818,Predicted intracellular proteins,Evidence at protein level,HPA012922,Approved,,Approved,Nucleus,"Endometrial cancer:8.73e-6 (favourable), Pancreatic cancer:6.15e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 38.6;stomach: 49.2,esophagus: 27.0,Cell line enhanced,,A-431: 13.9;CAPAN-2: 43.6;RT4: 27.0;T-47d: 21.2
10,ANXA8,ANX8,ENSG00000265190,Annexin A8,10,47460162-47484158,Predicted intracellular proteins,Evidence at protein level,"HPA045246, HPA047451",,,Approved,Nucleoplasm,"Pancreatic cancer:2.68e-4 (unfavourable), Head and neck cancer:6.07e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 229.1;skin: 368.9,urinary bladder: 64.2,Cell line enhanced,,HaCaT: 409.1;HBEC3-KT: 486.4;hTCEpi: 269.3
11,APCDD1,B7323,ENSG00000154856,APC down-regulated 1,18,10454628-10489948,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Endometrial cancer:6.39e-4 (favourable),Expressed in all,Tissue enhanced,,skin: 153.1,cerebral cortex: 60.6,Cell line enhanced,,AF22: 31.6;BJ hTERT+: 56.8;HaCaT: 37.9;HSkMC: 28.6
12,ARHGEF19,"FLJ33962, WGEF",ENSG00000142632,Rho guanine nucleotide exchange factor 19,1,16197854-16212609,Predicted intracellular proteins,Evidence at protein level,HPA068108,,,Approved,Nuclear bodies,"Renal cancer:8.88e-5 (unfavourable), Lung cancer:6.53e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 20.9,thyroid gland: 11.5,Cell line enhanced,,T-47d: 23.8
13,ARHGEF4,"ASEF, KIAA1112, STM6",ENSG00000136002,Rho guanine nucleotide exchange factor 4,2,130836916-131047263,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA018267,Approved,,,,Testis cancer:7.00e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 61.6;skin: 44.1,esophagus: 14.5,Cell line enhanced,,HaCaT: 31.5;hTCEpi: 52.8;SCLC-21H: 52.6
14,ARR3,ARRX,ENSG00000120500,Arrestin 3,X,70268305-70281840,Predicted intracellular proteins,Evidence at protein level,HPA063129,Supported,,,,,Not detected,Tissue enhanced,,skin: 2.7,lymph node: 1.1,Cell line enhanced,,Karpas-707: 1.5
15,ATG9B,"APG9L2, FLJ14885, NOS3AS, SONE",ENSG00000181652,Autophagy related 9B,7,151012209-151024499,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,esophagus: 9.2;placenta: 5.8;skin: 13.5,testis: 3.8,Cell line enhanced,,BEWO: 12.5;CAPAN-2: 3.7
16,ATP6V1C2,"ATP6C2, VMA5",ENSG00000143882,ATPase H+ transporting V1 subunit C2,2,10721649-10785110,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA034734, HPA067305",Approved,,Uncertain,Mitochondria,Renal cancer:1.12e-11 (unfavourable),Mixed,Tissue enhanced,,"cervix, uterine: 83.9;epididymis: 99.0;skin: 123.7",placenta: 55.1,Group enriched,9.0,BEWO: 71.4;SK-BR-3: 20.0
17,AWAT2,"DGAT2L4, MFAT",ENSG00000147160,Acyl-CoA wax alcohol acyltransferase 2,X,70040542-70049938,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA062748,Approved,,,,,Tissue enriched,Tissue enhanced,,breast: 2.0;skin: 1.2,testis: 0.5,Not detected,,
18,B3GNT4,"B3GN-T4, beta3Gn-T4",ENSG00000176383,"UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4",12,122203543-122208952,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA055261,Uncertain,,Approved,Nucleoli<br>Mitochondria,Renal cancer:3.52e-6 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 4.3;skin: 2.9,kidney: 1.9,Cell line enhanced,,HDLM-2: 4.5;hTCEpi: 4.9;T-47d: 5.0
19,BCL11A,"BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856",ENSG00000119866,B-cell CLL/lymphoma 11A,2,60451167-60553567,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB014891, HPA029003",Enhanced,,Enhanced,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,skin: 41.0,tonsil: 30.6,Cell line enhanced,,Daudi: 24.7;MOLT-4: 28.5;REH: 32.5;U-698: 43.2
20,BCL11B,"CTIP-2, CTIP2, hRIT1-alpha, ZNF856B",ENSG00000127152,B-cell CLL/lymphoma 11B,14,99169287-99271524,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA049117,Enhanced,Supported,Approved,Nucleus<br>Nucleoli fibrillar center,Urothelial cancer:7.48e-4 (favourable),Mixed,Tissue enhanced,,lymph node: 12.2;skin: 18.7,tonsil: 7.4,Cell line enriched,6.0,MOLT-4: 41.1
21,BCL2L10,"BCL-B, Boo, Diva",ENSG00000137875,BCL2 like 10,15,52109263-52112775,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA042222,Approved,,,,,Mixed,Tissue enhanced,,skin: 6.1,kidney: 3.3,Group enriched,8.0,NB-4: 21.5;SiHa: 4.5
22,BICDL1,"BICDR-1, CCDC64, FLJ26450",ENSG00000135127,BICD family like cargo adaptor 1,12,119989869-120094494,Predicted intracellular proteins,Evidence at protein level,HPA061116,Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Stomach cancer:1.21e-5 (favourable), Renal cancer:3.93e-5 (favourable), Head and neck cancer:3.15e-4 (favourable), Cervical cancer:6.50e-4 (favourable), Liver cancer:6.84e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 73.9;skin: 58.6,epididymis: 45.6,Cell line enhanced,,hTCEpi: 35.3;SCLC-21H: 36.3
23,BICDL2,CCDC64B,ENSG00000162069,BICD family like cargo adaptor 2,16,3027682-3036926,Predicted intracellular proteins,Evidence at protein level,HPA043251,Uncertain,,Approved,Intermediate filaments<br>Actin filaments<br>Cytosol,Urothelial cancer:9.04e-4 (favourable),Mixed,Tissue enhanced,,skin: 28.5,stomach: 17.2,Cell line enhanced,,BEWO: 14.7;CAPAN-2: 12.6;HaCaT: 19.6;MCF7: 17.2;T-47d: 13.1
24,C11orf80,"FLJ22531, TOPOVIBL",ENSG00000173715,Chromosome 11 open reading frame 80,11,66744451-66843328,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038932, HPA038933",Approved,,Approved,Centrosome,,Expressed in all,Tissue enhanced,,skin: 48.2,testis: 26.7,Mixed,,
25,C15orf62,LOC643338,ENSG00000188277,Chromosome 15 open reading frame 62,15,40770080-40772449,Predicted intracellular proteins,Evidence at protein level,HPA044636,Approved,,,,,Mixed,Tissue enhanced,,esophagus: 14.9;skin: 12.6,tonsil: 4.6,Cell line enhanced,,RPTEC TERT1: 13.6
26,C1QTNF9B,CTRP9B,ENSG00000205863,C1q and tumor necrosis factor related protein 9B,13,23890525-23902655,Predicted secreted proteins,Evidence at protein level,HPA056632,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,skin: 9.4,testis: 3.3,Not detected,,
27,C2CD4D,FAM148D,ENSG00000225556,C2 calcium dependent domain containing 4D,1,151837819-151840557,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,skin: 1.9,cerebral cortex: 1.2,Cell line enriched,8.0,HDLM-2: 17.9
28,C2orf54,FLJ22671,ENSG00000172478,Chromosome 2 open reading frame 54,2,240886048-240896889,Predicted intracellular proteins,Evidence at protein level,HPA052722,,,Approved,Nucleoplasm<br>Golgi apparatus,Endometrial cancer:2.77e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 112.1;skin: 51.5,tonsil: 25.5,Group enriched,7.0,CACO-2: 49.6;HaCaT: 39.3;SK-BR-3: 116.4
29,C3orf52,"FLJ23186, TTMP",ENSG00000114529,Chromosome 3 open reading frame 52,3,112086335-112131004,Predicted membrane proteins,Evidence at protein level,"HPA008119, HPA011968",Uncertain,,,,Pancreatic cancer:3.85e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 23.1,thyroid gland: 16.6,Cell line enhanced,,U-698: 37.5
30,CA12,HsT18816,ENSG00000074410,Carbonic anhydrase 12,15,63321378-63382161,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA008773, CAB025181, CAB062549, CAB068179, HPA073203",Enhanced,,Approved,Nucleus<br>Vesicles,Pancreatic cancer:3.80e-6 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 308.4;skin: 168.3,rectum: 102.9,Cell line enhanced,,A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
31,CALML3,CLP,ENSG00000178363,Calmodulin like 3,10,5524009-5526771,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010070, HPA044999",Approved,,,,,Group enriched,Tissue enhanced,,esophagus: 165.7;skin: 42.6,tonsil: 22.4,Group enriched,6.0,A-431: 12.2;hTCEpi: 3.8;RPMI-8226: 2.6
32,CAMSAP3,"KIAA1543, Nezha, PPP1R80",ENSG00000076826,Calmodulin regulated spectrin associated protein family member 3,19,7595902-7618304,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043830, HPA062149",Enhanced,,Approved,Nucleoplasm<br>Centrosome,Renal cancer:7.55e-7 (favourable),Expressed in all,Tissue enhanced,,skin: 22.1,duodenum: 15.2,Cell line enhanced,,CACO-2: 22.2
33,CAPNS2,"MGC12536, MGC14804",ENSG00000256812,Calpain small subunit 2,16,55566672-55567687,Predicted intracellular proteins,Evidence at protein level,"HPA059749, HPA076768",Enhanced,,Approved,Cytosol,,Group enriched,Tissue enhanced,,esophagus: 59.9;skin: 109.3,urinary bladder: 30.3,Cell line enriched,8.0,hTCEpi: 158.7
34,CARD14,"BIMP2, CARMA2, PSORS2",ENSG00000141527,Caspase recruitment domain family member 14,17,80169992-80209331,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 17.8,esophagus: 7.0,Cell line enhanced,,MCF7: 6.3;SK-BR-3: 8.0;T-47d: 22.6
35,CARD17,INCA,ENSG00000255221,Caspase recruitment domain family member 17,11,105092469-105101431,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 3.5,lymph node: 1.9,Cell line enriched,5.0,AN3-CA: 1.4
36,CARMIL3,"BC008134, C14orf121, crml-1, LRRC16B",ENSG00000186648,Capping protein regulator and myosin 1 linker 3,14,24052000-24069728,Predicted intracellular proteins,Evidence at protein level,HPA030596,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 6.7;skin: 6.2,testis: 3.0,Cell line enhanced,,Daudi: 7.8;HMC-1: 6.5;Karpas-707: 4.8;SCLC-21H: 12.8;SH-SY5Y: 5.6
37,CASZ1,"castor, cst, FLJ20321, SRG, ZNF693",ENSG00000130940,Castor zinc finger 1,1,10636604-10796650,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA028222, HPA029927",Approved,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,skin: 26.9,prostate: 15.9,Cell line enhanced,,HDLM-2: 12.4;SCLC-21H: 23.3;SK-BR-3: 14.1
38,CBLC,"CBL-3, CBL-SL, RNF57",ENSG00000142273,Cbl proto-oncogene C,19,44777869-44800634,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB008087, HPA035266",Approved,,Approved,Nucleoplasm,Renal cancer:3.11e-6 (favourable),Mixed,Tissue enhanced,,duodenum: 52.5;skin: 41.9;small intestine: 44.0,colon: 21.4,Cell line enhanced,,A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
39,CCER2,,ENSG00000262484,Coiled-coil glutamate rich protein 2,19,38908980-38912158,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA069716,Uncertain,,,,Urothelial cancer:2.32e-4 (favourable),Mixed,Tissue enhanced,,skin: 3.3,testis: 1.2,Mixed,,
40,CD1B,CD1,ENSG00000158485,CD1b molecule,1,158327951-158331531,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA021824,Approved,,,,,Mixed,Tissue enhanced,,rectum: 3.1;skin: 3.9,lymph node: 2.7,Cell line enriched,1556.0,MOLT-4: 465.4
41,CD1E,,ENSG00000158488,CD1e molecule,1,158353696-158357553,"CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA057769,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 18.3,tonsil: 10.4,Cell line enriched,980.0,MOLT-4: 1075.1
42,CDC42BPG,"DMPK2, HSMDPKIN, kappa-200, MRCKgamma",ENSG00000171219,CDC42 binding protein kinase gamma,11,64823387-64844569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027382, HPA061836",Enhanced,,Supported,Cytosol,Renal cancer:5.99e-13 (favourable),Mixed,Tissue enhanced,,skin: 35.6,parathyroid gland: 14.5,Cell line enhanced,,BEWO: 30.1;HaCaT: 21.0;MCF7: 25.1;SCLC-21H: 19.6
43,CDH3,"CDHP, PCAD",ENSG00000062038,Cadherin 3,16,68636189-68722616,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA001767, CAB002487",Enhanced,,Uncertain,Cell Junctions<br>Cytosol,"Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 31.9,ovary: 26.5,Cell line enhanced,,A-431: 89.4;HaCaT: 243.8;HBEC3-KT: 95.6;hTCEpi: 75.4;RPTEC TERT1: 88.7
44,CENPP,"CENP-P, RP11-19J3.3",ENSG00000188312,Centromere protein P,9,92325484-92620533,Predicted intracellular proteins,Evidence at protein level,"HPA021787, HPA058945",Uncertain,,Supported,Nucleus<br>Nucleoli,"Head and neck cancer:3.65e-4 (favourable), Cervical cancer:3.91e-4 (favourable)",Mixed,Tissue enhanced,,skin: 25.2,parathyroid gland: 8.0,Expressed in all,,
45,CGB7,CG-beta-a,ENSG00000196337,Chorionic gonadotropin beta subunit 7,19,49054275-49058860,Predicted secreted proteins,Evidence at protein level,"HPA038925, HPA038934",Supported,,Approved,Cytosol,,Not detected,Tissue enhanced,,skin: 3.8,"placenta,seminal vesicle,skeletal muscle: 1.0",Cell line enhanced,,BEWO: 4.7;HaCaT: 3.5;hTCEpi: 3.4;U-251 MG: 6.1
46,CLDN1,"ILVASC, SEMP1",ENSG00000163347,Claudin 1,3,190305701-190322475,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB002602, HPA048319",Enhanced,,,,"Endometrial cancer:2.00e-4 (unfavourable), Pancreatic cancer:5.23e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 306.2;smooth muscle: 186.0,liver: 158.4,Cell line enhanced,,EFO-21: 613.4;HaCaT: 206.6;hTCEpi: 206.7;RPTEC TERT1: 310.7;RT4: 210.1
47,CTD-2659N19.11,,ENSG00000283980,,19,12687998-12688422,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,skin: 1.2;testis: 1.6,thyroid gland: 0.8,Cell line enhanced,,HEK93: 2.0;MCF7: 1.6
48,CTD-3088G3.8,,ENSG00000188897,,16,11359845-11523588,Predicted intracellular proteins,Evidence at transcript level,HPA042154,Uncertain,,,,,Not detected,Tissue enhanced,,appendix: 5.3;skin: 4.3,testis: 2.8,Cell line enhanced,,Daudi: 2.2;HDLM-2: 3.2
49,CTSV,"CTSL2, CTSU",ENSG00000136943,Cathepsin V,9,97029679-97039643,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB017112,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 69.3;skin: 64.2;testis: 131.8",placenta: 25.9,Cell line enriched,7.0,BEWO: 563.7
50,CXCL14,"BMAC, bolekine, BRAK, Kec, KS1, MIP-2g, NJAC, SCYB14",ENSG00000145824,C-X-C motif chemokine ligand 14,5,135570679-135579279,Predicted secreted proteins,Evidence at protein level,CAB029996,Uncertain,,,,"Cervical cancer:1.71e-4 (favourable), Colorectal cancer:4.52e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 874.5,kidney: 335.8,Group enriched,12.0,HAP1: 60.3;hTCEpi: 55.4;RPTEC TERT1: 157.5;U-2 OS: 88.6
51,CYP27C1,FLJ16008,ENSG00000186684,Cytochrome P450 family 27 subfamily C member 1,2,127184120-127220078,Predicted intracellular proteins,Evidence at protein level,"HPA062460, HPA068731",,,Supported,Vesicles,,Mixed,Tissue enhanced,,skin: 6.8,"cervix, uterine: 2.4",Cell line enhanced,,HDLM-2: 13.5;TIME: 11.6;U-138 MG: 13.8
52,CYP2W1,"FLJ20359, MGC34287",ENSG00000073067,Cytochrome P450 family 2 subfamily W member 1,7,983199-989640,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA012753,Uncertain,,,,Urothelial cancer:5.85e-4 (unfavourable),Group enriched,Tissue enhanced,,adrenal gland: 5.5;duodenum: 6.2;skin: 9.7,placenta: 1.4,Group enriched,7.0,CACO-2: 11.2;Hep G2: 33.8
53,CYP4F22,FLJ39501,ENSG00000171954,Cytochrome P450 family 4 subfamily F member 22,19,15508493-15552317,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA058960,Uncertain,,,,,Group enriched,Tissue enhanced,,esophagus: 14.0;skin: 34.3,seminal vesicle: 9.1,Cell line enhanced,,MCF7: 1.3
54,CYSRT1,"C9orf169, MGC59937",ENSG00000197191,Cysteine rich tail 1,9,137224635-137226311,Predicted intracellular proteins,Evidence at protein level,"HPA021883, HPA021886",Approved,,Approved,Nuclear speckles<br>Vesicles<br>Midbody,,Expressed in all,Tissue enhanced,,esophagus: 45.6;skin: 12.2,tonsil: 6.3,Cell line enhanced,,A-431: 11.7;CAPAN-2: 14.5;HaCaT: 16.3;MCF7: 20.0
55,DAPL1,,ENSG00000163331,Death associated protein like 1,2,158795317-158862781,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046937, HPA058635",Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies<br>Microtubules,Cervical cancer:8.43e-4 (favourable),Group enriched,Tissue enhanced,,epididymis: 238.2;esophagus: 243.7;skin: 219.0,fallopian tube: 128.4,Group enriched,5.0,HaCaT: 3.5;hTCEpi: 16.6;SCLC-21H: 6.9;U-87 MG: 8.2
56,DCST2,FLJ32934,ENSG00000163354,DC-STAMP domain containing 2,1,155018520-155033781,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,skin: 5.0;testis: 4.2,"duodenum,fallopian tube: 1.3",Cell line enhanced,,U-266/70: 1.1
57,DEGS2,"C14orf66, DES2, FADS8",ENSG00000168350,"Delta 4-desaturase, sphingolipid 2",14,100143957-100160163,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046644,,,Approved,Nucleus<br>Nucleoli,"Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable)",Mixed,Tissue enhanced,,skin: 31.4;small intestine: 38.7,duodenum: 24.8,Cell line enriched,16.0,T-47d: 98.2
58,DENND2C,"dJ1156J9.1, DKFZp686G0351, DKFZp779P1149, FLJ37099, RP5-1156J9.1",ENSG00000175984,DENN domain containing 2C,1,114582848-114670422,Predicted intracellular proteins,Evidence at protein level,HPA054955,Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,esophagus: 19.5;skeletal muscle: 14.3;skin: 14.8,testis: 10.0,Cell line enhanced,,U-2197: 10.9;U-266/70: 19.3
59,DLK2,"EGFL9, MGC2487",ENSG00000171462,Delta like non-canonical Notch ligand 2,6,43450352-43456632,Predicted membrane proteins,Evidence at transcript level,"HPA061223, HPA068672",Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,prostate: 9.3;skin: 14.5,seminal vesicle: 7.5,Cell line enhanced,,HaCaT: 21.0;hTCEpi: 27.7
60,DLX5,,ENSG00000105880,Distal-less homeobox 5,7,97020392-97025097,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA005670,Approved,,Approved,Nucleus,,Tissue enriched,Tissue enhanced,,endometrium: 20.2;placenta: 13.5;skin: 17.1,"cervix, uterine: 9.6",Group enriched,5.0,BEWO: 41.0;HAP1: 24.0
61,DUOX1,"LNOX1, NOXEF1, THOX1",ENSG00000137857,Dual oxidase 1,15,45129933-45165576,"Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA023544,Approved,,,,Cervical cancer:4.31e-6 (favourable),Tissue enhanced,Tissue enhanced,,skin: 96.9;thyroid gland: 92.6,esophagus: 73.2,Cell line enhanced,,HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
62,DUOXA1,"FLJ32334, mol, NIP, NUMBIP",ENSG00000140254,Dual oxidase maturation factor 1,15,45117367-45129938,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041578,Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 122.2;skin: 107.9;thyroid gland: 112.0,epididymis: 60.3,Cell line enriched,9.0,HaCaT: 92.0
63,EFNA3,"Ehk1-L, EPLG3, LERK3",ENSG00000143590,Ephrin A3,1,155078872-155087538,"Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB010494,Uncertain,,,,"Renal cancer:9.66e-10 (unfavourable), Liver cancer:2.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 51.3,cerebral cortex: 17.0,Cell line enhanced,,HAP1: 19.5;SCLC-21H: 32.5;T-47d: 24.4
64,EGLN3,"HIFPH3, PHD3",ENSG00000129521,Egl-9 family hypoxia inducible factor 3,14,33924231-34462774,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA064895,,,Approved,Cytosol,"Liver cancer:2.14e-5 (unfavourable), Renal cancer:2.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 98.0,heart muscle: 62.0,Cell line enhanced,,RH-30: 43.2;RT4: 97.7
65,ELOVL3,CIG-30,ENSG00000119915,ELOVL fatty acid elongase 3,10,102226328-102229589,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA036236,Supported,,Approved,Vesicles<br>Cytosol,Endometrial cancer:6.25e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,adipose tissue: 3.6;breast: 4.4;skin: 3.4,testis: 2.3,Cell line enhanced,,HSkMC: 10.4;SiHa: 24.5
66,ELOVL4,"CT118, SCA34, STGD2, STGD3",ENSG00000118402,ELOVL fatty acid elongase 4,6,79914812-79947580,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:6.27e-4 (unfavourable),Mixed,Tissue enhanced,,cerebral cortex: 24.0;skin: 50.7,parathyroid gland: 15.7,Cell line enhanced,,MOLT-4: 25.9
67,EPHB3,"ETK2, Hek2, Tyro6",ENSG00000182580,EPH receptor B3,3,184561784-184582409,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA007698, HPA008184, CAB034350",Enhanced,,,,Renal cancer:7.88e-5 (unfavourable),Expressed in all,Tissue enhanced,,skin: 45.4,stomach: 18.1,Cell line enhanced,,BEWO: 27.9;HaCaT: 35.7;SK-BR-3: 23.1;T-47d: 19.3
68,EPHB6,HEP,ENSG00000106123,EPH receptor B6,7,142855061-142871094,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA035784,,,Approved,Nuclear speckles,"Urothelial cancer:4.68e-5 (favourable), Cervical cancer:1.80e-4 (favourable), Glioma:6.96e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 22.5;skin: 25.0,"cervix, uterine: 7.6",Group enriched,5.0,MOLT-4: 25.8;RT4: 47.4
69,EPPK1,EPIPL1,ENSG00000261150,Epiplakin 1,8,143857324-143878464,Predicted intracellular proteins,Evidence at protein level,"HPA066808, HPA067357, HPA069333",Approved,,Enhanced,Intermediate filaments,"Endometrial cancer:5.52e-5 (unfavourable), Pancreatic cancer:3.94e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 11.2,small intestine: 2.9,Cell line enhanced,,BEWO: 13.8;EFO-21: 12.5;HaCaT: 12.0;HeLa: 15.1;MCF7: 15.3
70,EPS8L1,"DRC3, FLJ20258, MGC23164, MGC4642",ENSG00000131037,EPS8 like 1,19,55072020-55087923,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA041851, HPA043545",Uncertain,,Supported,Cytosol,Colorectal cancer:4.44e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 18.4;stomach: 23.5,esophagus: 9.0,Cell line enhanced,,BEWO: 51.9;T-47d: 24.8
71,ESPN,DFNB36,ENSG00000187017,Espin,1,6424788-6461370,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028674, HPA060220",Enhanced,,Approved,Vesicles,,Mixed,Tissue enhanced,,skin: 96.5;testis: 118.3,small intestine: 77.3,Cell line enhanced,,BEWO: 42.8;SK-BR-3: 110.9;T-47d: 47.8
72,ESYT3,"CHR3SYT, FAM62C",ENSG00000158220,Extended synaptotagmin 3,3,138434586-138481686,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA039200,Approved,,,,Lung cancer:8.30e-4 (favourable),Tissue enhanced,Tissue enhanced,,lung: 8.4;skin: 7.5;thyroid gland: 8.5,endometrium: 3.7,Cell line enhanced,,NTERA-2: 4.1;SCLC-21H: 5.2;SiHa: 1.9
73,EVPLL,,ENSG00000214860,Envoplakin like,17,18377662-18389647,Predicted intracellular proteins,Evidence at transcript level,HPA045728,Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,,Not detected,Tissue enhanced,,esophagus: 1.7;skin: 3.0;testis: 1.5,lung: 0.8,Cell line enhanced,,HeLa: 1.2;hTCEpi: 4.7;RT4: 1.8;SiHa: 1.3;T-47d: 1.9
74,EXPH5,SLAC2-B,ENSG00000110723,Exophilin 5,11,108505431-108593738,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Endometrial cancer:3.42e-6 (favourable), Head and neck cancer:1.46e-4 (favourable), Renal cancer:2.43e-4 (favourable), Lung cancer:5.12e-4 (favourable)",Mixed,Tissue enhanced,,parathyroid gland: 16.1;skin: 31.3,esophagus: 8.2,Cell line enhanced,,hTERT-HME1: 8.7;RT4: 16.3
75,FAM110A,"bA371L19.3, C20orf55",ENSG00000125898,Family with sequence similarity 110 member A,20,833715-857463,Predicted intracellular proteins,Evidence at protein level,"CAB034110, HPA069240",Uncertain,,Supported,Nucleus<br>Vesicles<br>Cytosol,Renal cancer:4.42e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 31.3,spleen: 21.3,Cell line enhanced,,SK-BR-3: 62.8
76,FAM180B,LOC399888,ENSG00000196666,Family with sequence similarity 180 member B,11,47586693-47589194,Predicted intracellular proteins,Evidence at transcript level,HPA029408,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,breast: 6.9;skin: 4.4,adipose tissue: 4.1,Cell line enhanced,,SK-MEL-30: 1.8;U-937: 1.3
77,FAM212A,"C3orf54, INKA1",ENSG00000185614,Family with sequence similarity 212 member A,3,49803254-49805030,Predicted intracellular proteins,Evidence at protein level,HPA041879,Uncertain,,Approved,Nucleoplasm<br>Vesicles,Head and neck cancer:1.96e-4 (favourable),Expressed in all,Tissue enhanced,,skin: 24.4,lung: 7.0,Cell line enhanced,,HEL: 60.9;HMC-1: 39.3;THP-1: 28.1;U-937: 27.1
78,FAM25A,bA96C23.5,ENSG00000188100,Family with sequence similarity 25 member A,10,87020306-87024730,Predicted intracellular proteins,Evidence at transcript level,HPA044808,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 315.5;skin: 125.9,tonsil: 54.6,Group enriched,6.0,A-431: 22.6;SK-BR-3: 55.0
79,FAM46B,MGC16491,ENSG00000158246,Family with sequence similarity 46 member B,1,27005020-27012836,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 59.9;skin: 39.4,seminal vesicle: 22.1,Cell line enhanced,,hTCEpi: 45.0;NTERA-2: 32.9
80,FAM57A,"CT120, FLJ22282",ENSG00000167695,Family with sequence similarity 57 member A,17,732412-742972,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Endometrial cancer:3.53e-6 (favourable), Renal cancer:1.44e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 82.7,esophagus: 25.9,Expressed in all,,
81,FAM83B,"C6orf143, FLJ30642",ENSG00000168143,Family with sequence similarity 83 member B,6,54846771-54942022,Predicted intracellular proteins,Evidence at protein level,"HPA031464, HPA031465",Enhanced,,,,"Urothelial cancer:1.86e-5 (unfavourable), Lung cancer:1.48e-4 (unfavourable), Pancreatic cancer:7.60e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,skin: 27.3,esophagus: 17.7,Cell line enhanced,,A-431: 17.1;HaCaT: 18.9;hTCEpi: 15.2;hTERT-HME1: 21.2;RT4: 19.6
82,FAM83G,"FLJ41564, PAWS1",ENSG00000188522,Family with sequence similarity 83 member G,17,18968789-19004804,Predicted intracellular proteins,Evidence at protein level,"HPA023369, HPA023940",Enhanced,,Supported,Cytosol,"Stomach cancer:7.58e-6 (favourable), Liver cancer:8.29e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 64.4,esophagus: 24.2,Mixed,,
83,FAM83H,FLJ46072,ENSG00000180921,Family with sequence similarity 83 member H,8,143723933-143733801,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA024505, HPA024604",Enhanced,,Approved,Cytosol,"Lung cancer:3.77e-4 (unfavourable), Stomach cancer:4.42e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 17.2,esophagus: 10.3,Cell line enhanced,,HaCaT: 37.2;MCF7: 45.2
84,FAM83H-AS1,onco-lncRNA-3,ENSG00000203499,FAM83H antisense RNA 1 (head to head),8,143734140-143790644,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,epididymis: 26.2;skin: 34.3,esophagus: 13.0,Cell line enhanced,,HaCaT: 26.1;hTCEpi: 25.7;MCF7: 55.1;T-47d: 60.5
85,FAT2,"CDHF8, CDHR9, HFAT2, MEGF1",ENSG00000086570,FAT atypical cadherin 2,5,151504093-151568944,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,CAB033680,Enhanced,,,,,Group enriched,Tissue enhanced,,skin: 66.5,esophagus: 14.3,Group enriched,9.0,BEWO: 33.8;EFO-21: 19.8;HaCaT: 45.7;HBEC3-KT: 16.9;hTCEpi: 51.0
86,FBXO27,"Fbg5, Fbx27",ENSG00000161243,F-box protein 27,19,38990714-39032785,Predicted intracellular proteins,Evidence at protein level,"HPA046800, HPA062242",Approved,,Approved,Nucleoplasm,"Endometrial cancer:3.53e-5 (unfavourable), Breast cancer:2.15e-4 (favourable), Glioma:7.83e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 22.7,esophagus: 8.4,Cell line enhanced,,RT4: 14.1
87,FGF11,"FHF3, FLJ16061, MGC102953, MGC45269",ENSG00000161958,Fibroblast growth factor 11,17,7438273-7444937,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA066605, HPA075188",Enhanced,,Approved,Centrosome,,Mixed,Tissue enhanced,,adrenal gland: 17.3;skin: 13.7,cerebral cortex: 10.3,Cell line enhanced,,HaCaT: 16.3
88,FGF22,,ENSG00000070388,Fibroblast growth factor 22,19,639879-644371,"Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,skin: 8.5,cerebral cortex: 2.0,Cell line enhanced,,AN3-CA: 1.8
89,FOXN1,"FKHL20, RONU, WHN",ENSG00000109101,Forkhead box N1,17,28506243-28538896,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,"Head and neck cancer:5.00e-4 (favourable), Cervical cancer:6.43e-4 (favourable)",Tissue enhanced,Tissue enhanced,,esophagus: 7.2;skin: 35.2,tonsil: 5.1,Cell line enriched,8.0,HaCaT: 10.3
90,GAL3ST4,FLJ12116,ENSG00000197093,Galactose-3-O-sulfotransferase 4,7,100159244-100168750,Predicted membrane proteins,Evidence at protein level,"HPA038137, HPA038138",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Ovarian cancer:2.57e-4 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 32.6,smooth muscle: 14.7,Cell line enhanced,,WM-115: 42.3
91,GATA3,HDR,ENSG00000107485,GATA binding protein 3,10,8053604-8075198,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB016217, HPA029730",Enhanced,,Supported,Nucleoplasm,Renal cancer:3.13e-4 (unfavourable),Group enriched,Tissue enhanced,,parathyroid gland: 235.0;skin: 148.9,placenta: 44.3,Cell line enhanced,,BEWO: 172.2;MCF7: 354.3;RT4: 149.5;SH-SY5Y: 145.4;T-47d: 506.9
92,GDPD2,"FLJ20207, GDE3, OBDPF",ENSG00000130055,Glycerophosphodiester phosphodiesterase domain containing 2,X,70423031-70433390,"Enzymes, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 50.8;spleen: 60.0,small intestine: 20.0,Group enriched,8.0,AF22: 8.8;NTERA-2: 19.3
93,GJB3,"CX31, DFNA2, EKV",ENSG00000188910,Gap junction protein beta 3,1,34781189-34786369,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA074472,,,Supported,Vesicles<br>Cell Junctions,"Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 33.6;skin: 77.3,tonsil: 11.6,Cell line enhanced,,A-431: 76.8;CAPAN-2: 106.8;HaCaT: 87.5;HBEC3-KT: 60.8;hTCEpi: 98.5
94,GPC1,glypican,ENSG00000063660,Glypican 1,2,240435671-240468078,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030571,Approved,,Supported,Plasma membrane<br>Cytosol,"Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 265.8,prostate: 67.5,Mixed,,
95,GPC2,"cerebroglycan, DKFZp547M109, FLJ38962",ENSG00000213420,Glypican 2,7,100169606-100177372,Predicted secreted proteins,Evidence at protein level,"CAB025423, HPA053945",Uncertain,,Uncertain,Nucleus<br>Nucleoli<br>Golgi apparatus,Urothelial cancer:9.94e-4 (favourable),Mixed,Tissue enhanced,,skin: 5.7;testis: 10.1,cerebral cortex: 3.4,Cell line enhanced,,AF22: 39.1;SH-SY5Y: 46.0
96,GPR87,GPR95,ENSG00000138271,G protein-coupled receptor 87,3,151294086-151316952,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA066313,,,Approved,Nucleoplasm<br>Lipid droplets<br>Mitochondria,Pancreatic cancer:4.62e-6 (unfavourable),Group enriched,Tissue enhanced,,esophagus: 29.3;skin: 29.8,placenta: 12.0,Cell line enhanced,,A-431: 87.7;HaCaT: 68.9;HBEC3-KT: 74.5;hTCEpi: 98.3;hTERT-HME1: 43.6
97,GPRIN2,"KIAA0514, MGC15171",ENSG00000204175,G protein regulated inducer of neurite outgrowth 2,10,46549044-46555530,Predicted intracellular proteins,Evidence at protein level,HPA038129,Approved,,Approved,Nucleoplasm,"Endometrial cancer:8.60e-8 (unfavourable), Head and neck cancer:3.47e-4 (favourable)",Mixed,Tissue enhanced,,lung: 18.0;skin: 18.8,small intestine: 11.7,Group enriched,5.0,A-431: 12.9;A549: 38.1;SiHa: 8.3;SK-BR-3: 17.1
98,GRHL1,"LBP-32, MGR, TFCP2L2",ENSG00000134317,Grainyhead like transcription factor 1,2,9951693-10002277,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA005798, HPA006420",Enhanced,,Enhanced,Nucleus<br>Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,esophagus: 111.4;skin: 106.8,parathyroid gland: 50.3,Cell line enhanced,,BEWO: 205.8;SK-BR-3: 84.4
99,GSDMC,MLZE,ENSG00000147697,Gasdermin C,8,129748196-129786888,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA023670, HPA024767, HPA026317",Supported,,Enhanced,Mitochondria,,Group enriched,Tissue enhanced,,esophagus: 20.0;skin: 44.3;spleen: 21.6,tonsil: 6.5,Cell line enhanced,,A-431: 13.0;HaCaT: 3.1;hTCEpi: 4.5;HUVEC TERT2: 5.2;TIME: 4.3
100,HES2,bHLHb40,ENSG00000069812,Hes family bHLH transcription factor 2,1,6412418-6424670,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA039462,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 17.0,placenta: 9.8,Cell line enhanced,,BEWO: 19.0;HaCaT: 33.0;HBEC3-KT: 23.1;TIME: 44.9
101,HLA-DQB2,HLA-DXB,ENSG00000232629,"Major histocompatibility complex, class II, DQ beta 2",6,32756098-32763534,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Breast cancer:5.55e-4 (favourable),Expressed in all,Tissue enhanced,,lung: 8.1;skin: 13.3,tonsil: 5.9,Not detected,,
102,HOPX,"HOP, LAGY, NECC1, OB1, SMAP31",ENSG00000171476,HOP homeobox,4,56647988-56681899,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB018632, HPA030180",Enhanced,,,,,Mixed,Tissue enhanced,,epididymis: 658.1;skin: 839.4,esophagus: 525.5,Cell line enhanced,,HDLM-2: 28.9;HUVEC TERT2: 55.7;RT4: 40.2;TIME: 62.0
103,HOXC11,HOX3H,ENSG00000123388,Homeobox C11,12,53973126-53977643,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,HPA038291,Uncertain,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,skin: 2.2,testis: 1.1,Cell line enhanced,,AN3-CA: 32.1;BJ hTERT+: 14.2;T-47d: 25.7
104,HR,"ALUNC, AU",ENSG00000168453,"HR, lysine demethylase and nuclear receptor corepressor",8,22114415-22133384,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA054888,,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,skin: 58.9,cerebral cortex: 11.9,Cell line enhanced,,HaCaT: 70.7;SiHa: 29.4;T-47d: 27.6
105,IGFL4,,ENSG00000204869,IGF like family member 4,19,46039748-46077118,Predicted intracellular proteins,Evidence at transcript level,HPA047655,Approved,,Approved,Cytosol,,Mixed,Tissue enhanced,,skin: 8.2,cerebral cortex: 2.6,Cell line enhanced,,A549: 3.5;HaCaT: 3.0
106,IGSF22,"FLJ37794, IGFN2",ENSG00000179057,Immunoglobulin superfamily member 22,11,18704305-18726230,Predicted intracellular proteins,Evidence at protein level,CAB026459,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 1.2;testis: 1.0,cerebral cortex: 0.8,Not detected,,
107,IGSF9,"IGSF9A, KIAA1355, Nrt1",ENSG00000085552,Immunoglobulin superfamily member 9,1,159927039-159945604,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA037753,Uncertain,,,,Endometrial cancer:5.16e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 28.1,stomach: 13.2,Cell line enhanced,,BEWO: 25.2;HaCaT: 34.4;SCLC-21H: 40.2
108,IL18,"IGIF, IL-18, IL-1g, IL1F4",ENSG00000150782,Interleukin 18,11,112143251-112164117,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003980, CAB007772",Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,Colorectal cancer:2.78e-4 (favourable),Expressed in all,Tissue enhanced,,esophagus: 133.0;skin: 171.5,lymph node: 71.9,Cell line enhanced,,CAPAN-2: 155.6;HaCaT: 143.7;hTCEpi: 132.7;U-2 OS: 214.0
109,IL1RL2,"IL1R-rp2, IL1RRP2",ENSG00000115598,Interleukin 1 receptor like 2,2,102186973-102240002,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA015485,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 15.5,parathyroid gland: 8.5,Cell line enhanced,,A-431: 7.2;ASC TERT1: 3.6;HaCaT: 3.3;HSkMC: 3.1
110,IL20RA,"IL-20R1, ZCYTOR7",ENSG00000016402,Interleukin 20 receptor subunit alpha,6,136999971-137045180,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB024990, HPA042281",Approved,,Approved,Cytosol,"Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable)",Mixed,Tissue enhanced,,skin: 45.0,breast: 33.5,Group enriched,7.0,CAPAN-2: 8.4;HaCaT: 6.1;RT4: 9.2;SH-SY5Y: 11.4;T-47d: 10.0
111,IL34,"C16orf77, IL-34, MGC34647",ENSG00000157368,Interleukin 34,16,70579895-70660682,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,"Renal cancer:3.52e-8 (unfavourable), Cervical cancer:7.41e-4 (favourable), Head and neck cancer:9.69e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 58.0;spleen: 145.6,cerebral cortex: 20.8,Cell line enhanced,,NTERA-2: 5.5;U-138 MG: 3.5
112,IL36B,"FIL1, FILI-(ETA), IL-1F8, IL-1H2, IL1-ETA, IL1F8, IL1H2, MGC126880, MGC126882",ENSG00000136696,"Interleukin 36, beta",2,113022091-113052867,Predicted intracellular proteins,Evidence at transcript level,HPA035664,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 2.2;skin: 7.3;tonsil: 3.4,breast: 1.2,Cell line enriched,21.0,U-87 MG: 71.9
113,IMPG1,"GP147, IPM150, SPACR",ENSG00000112706,Interphotoreceptor matrix proteoglycan 1,6,75921115-76072678,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027142, HPA030332, HPA030333",Enhanced,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.5;skin: 1.6,"duodenum,small intestine: 0.9",Cell line enhanced,,HaCaT: 1.0
114,IRX4,,ENSG00000113430,Iroquois homeobox 4,5,1877413-1887236,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA064094,,,Uncertain,Nucleus<br>Vesicles,,Mixed,Tissue enhanced,,prostate: 5.8;skin: 6.9,esophagus: 1.4,Cell line enhanced,,BEWO: 43.3;HaCaT: 15.1;HBEC3-KT: 6.7
115,IRX5,IRX-2a,ENSG00000176842,Iroquois homeobox 5,16,54930862-54934485,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047130,,,Approved,Nuclear speckles<br>Microtubules<br>Cytosol,Lung cancer:4.59e-4 (favourable),Tissue enhanced,Tissue enhanced,,breast: 17.9;lung: 9.6;skin: 10.1,salivary gland: 4.6,Cell line enhanced,,RPTEC TERT1: 20.1;T-47d: 34.4
116,JAG2,,ENSG00000184916,Jagged 2,14,105140981-105168824,Predicted membrane proteins,Evidence at protein level,"CAB025481, HPA030636, HPA050567",Approved,,Supported,Vesicles<br>Cytosol,,Expressed in all,Tissue enhanced,,skin: 22.5,adipose tissue: 6.5,Cell line enhanced,,HaCaT: 54.2;SCLC-21H: 36.3
117,KLF5,"BTEB2, CKLF, IKLF",ENSG00000102554,Kruppel like factor 5,13,73054976-73077542,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA040398,Approved,,Supported,Nucleoplasm<br>Golgi apparatus<br>Vesicles,Pancreatic cancer:2.55e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 279.6,esophagus: 216.2,Cell line enhanced,,HaCaT: 113.4;hTCEpi: 113.2;RT4: 108.4;SiHa: 121.1
118,KLF8,"BKLF3, DXS741, ZNF741",ENSG00000102349,Kruppel like factor 8,X,56232421-56287889,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071740,,,Supported,Nucleoplasm,Head and neck cancer:3.32e-4 (favourable),Mixed,Tissue enhanced,,skin: 33.8,esophagus: 16.9,Cell line enhanced,,hTCEpi: 9.9;RT4: 9.7;SK-BR-3: 7.9;T-47d: 18.2
119,KLK10,"NES1, PRSSL1",ENSG00000129451,Kallikrein related peptidase 10,19,51012739-51020175,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at protein level,HPA017195,,,Uncertain,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 138.2;skin: 52.7,tonsil: 45.8,Group enriched,5.0,CAPAN-2: 200.9;HaCaT: 307.2
120,KLK11,"PRSS20, TLSP",ENSG00000167757,Kallikrein related peptidase 11,19,51022216-51028039,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB026340,Approved,,,,"Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 225.7;skin: 214.5,prostate: 104.9,Cell line enhanced,,CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6
121,KREMEN2,"KRM2, MGC10791",ENSG00000131650,Kringle containing transmembrane protein 2,16,2963944-2968383,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA003223,Uncertain,,Approved,Nucleoli,Lung cancer:8.98e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 6.9,cerebral cortex: 2.1,Cell line enhanced,,HMC-1: 24.6;RPMI-8226: 19.1
122,KRT23,"CK23, DKFZP434G032, HAIK1, K23, MGC26158",ENSG00000108244,Keratin 23,17,40922696-40937634,Predicted intracellular proteins,Evidence at protein level,"HPA012050, HPA016959, CAB017091",Approved,,Approved,Intermediate filaments<br>Cytosol,Urothelial cancer:8.26e-4 (unfavourable),Mixed,Tissue enhanced,,placenta: 68.6;skin: 70.9,salivary gland: 41.2,Group enriched,8.0,HBEC3-KT: 28.8;Hep G2: 17.3;T-47d: 63.7
123,KRT36,KRTHA6,ENSG00000126337,Keratin 36,17,41486136-41492546,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 2.1;tonsil: 1.5,"cervix, uterine,spleen: 0.5",Cell line enriched,11.0,Karpas-707: 2.2
124,KRT37,KRTHA7,ENSG00000108417,Keratin 37,17,41420753-41424523,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,skin: 1.2,"cervix, uterine: 0.3",Not detected,,
125,KRT80,KB20,ENSG00000167767,Keratin 80,12,52168996-52192000,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA077836, HPA077918",,,Enhanced,Intermediate filaments,Breast cancer:1.05e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 125.0,tonsil: 37.7,Cell line enhanced,,A-431: 176.4;MCF7: 219.4;U-2 OS: 184.3
126,KRT9,"CK-9, EPPK, K9",ENSG00000171403,Keratin 9,17,41565841-41572058,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007261, CAB037322",Supported,,,,,Tissue enriched,Tissue enhanced,,skin: 2.9,adrenal gland: 0.7,Cell line enhanced,,BEWO: 6.7;HaCaT: 14.8;U-937: 4.1
127,KY,FLJ33207,ENSG00000174611,Kyphoscoliosis peptidase,3,134603138-134651636,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036492, HPA036668",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,skin: 11.0,parathyroid gland: 9.3,Cell line enhanced,,Karpas-707: 1.6;U-2197: 2.7;U-87 MG: 8.6
128,LAD1,,ENSG00000159166,Ladinin 1,1,201373244-201399915,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007256, HPA028732",Enhanced,,Enhanced,Actin filaments,Lung cancer:6.73e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 291.7;skin: 236.6,small intestine: 93.9,Cell line enhanced,,A-431: 173.4;CAPAN-2: 150.1;HaCaT: 219.8;MCF7: 165.3;RT4: 146.2;SK-BR-3: 220.4
129,LAMA5,,ENSG00000130702,Laminin subunit alpha 5,20,62307955-62367312,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA054609, CAB078157",Enhanced,,Supported,Nucleoplasm<br>Vesicles,,Expressed in all,Tissue enhanced,,skin: 42.1,placenta: 28.9,Cell line enhanced,,CACO-2: 131.3
130,LCE3D,"LEP16, SPRL6A, SPRL6B",ENSG00000163202,Late cornified envelope 3D,1,152579381-152580504,Predicted intracellular proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,skin: 26.5;tonsil: 79.8,esophagus: 11.6,Group enriched,5.0,hTCEpi: 3.2;hTERT-HME1: 3.1
131,LMO1,"RBTN1, RHOM1, TTG1",ENSG00000166407,LIM domain only 1,11,8224304-8268716,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,skeletal muscle: 10.1;skin: 5.9,epididymis: 2.0,Group enriched,6.0,HeLa: 22.0;SCLC-21H: 14.8;SH-SY5Y: 41.0;SiHa: 8.4
132,LRP4,"CLSS, LRP-4, MEGF7, SOST2",ENSG00000134569,LDL receptor related protein 4,11,46856868-46918642,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA011934, HPA012300",Approved,,Uncertain,Nucleus<br>Nucleoli<br>Mitochondria,,Expressed in all,Tissue enhanced,,cerebral cortex: 35.4;skin: 37.9,parathyroid gland: 13.1,Cell line enhanced,,AF22: 21.2
133,LTB4R,"BLTR, CMKRL1, GPR16, LTB4R1, P2RY7, P2Y7",ENSG00000213903,Leukotriene B4 receptor,14,24311450-24318036,"G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA003873,Approved,,,,"Renal cancer:3.44e-15 (unfavourable), Pancreatic cancer:1.85e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 165.8,esophagus: 42.6,Expressed in all,,
134,LTB4R2,"BLT2, BLTR2, JULF2, NOP9",ENSG00000213906,Leukotriene B4 receptor 2,14,24305734-24312053,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022689, HPA029680, HPA072921",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,skin: 40.5,spleen: 10.3,Cell line enhanced,,HaCaT: 24.8
135,LY6G6E,"C6orf22, G6e",ENSG00000255552,Lymphocyte antigen 6 family member G6E,6,31711771-31714065,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA056234,,,Approved,Nucleus,,Not detected,Tissue enhanced,,skin: 1.2;thyroid gland: 1.0,bone marrow: 0.8,Cell line enriched,103.0,HEL: 21.3
136,LYPD5,FLJ30469,ENSG00000159871,LY6/PLAUR domain containing 5,19,43795929-43827206,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042511, HPA054670",Approved,,Approved,Nucleoplasm<br>Cytosol,Cervical cancer:5.84e-4 (favourable),Tissue enhanced,Tissue enhanced,,skin: 43.7,testis: 12.3,Cell line enhanced,,A-431: 3.3;BEWO: 5.5;HaCaT: 5.3
137,LYPD6B,"CT116, LYPD7",ENSG00000150556,LY6/PLAUR domain containing 6B,2,149038107-149215262,"Predicted secreted proteins, Transporters",Evidence at transcript level,HPA049239,Uncertain,,,,,Mixed,Tissue enhanced,,gallbladder: 58.6;skin: 56.5,testis: 42.4,Cell line enhanced,,fHDF/TERT166: 50.2;LHCN-M2: 85.2;RT4: 43.6
138,MAP3K6,"ASK2, MAPKKK6, MEKK6",ENSG00000142733,Mitogen-activated protein kinase kinase kinase 6,1,27355184-27366892,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051192,Approved,,Approved,Nucleus<br>Plasma membrane<br>Actin filaments<br>Cytosol,"Glioma:1.73e-4 (unfavourable), Head and neck cancer:7.26e-4 (favourable), Liver cancer:8.76e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 114.9,esophagus: 41.2,Mixed,,
139,MATN4,,ENSG00000124159,Matrilin 4,20,45293445-45308529,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,breast: 3.0;pancreas: 5.9;skin: 3.5,"cervix, uterine: 1.4",Cell line enhanced,,NB-4: 1.7;U-937: 1.0
140,MEGF6,EGFL3,ENSG00000162591,Multiple EGF like domains 6,1,3489920-3611495,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA052129,Uncertain,,Approved,Microtubules<br>Cytokinetic bridge,"Colorectal cancer:3.08e-4 (unfavourable), Head and neck cancer:6.57e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 48.2,gallbladder: 17.0,Cell line enhanced,,BJ: 37.3;HeLa: 26.6;U-2197: 36.2
141,MICALCL,FLJ14966,ENSG00000133808,MICAL C-terminal like,11,12276080-12359144,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039895, HPA040438",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,skin: 17.3;testis: 13.4,lung: 10.3,Cell line enhanced,,HBEC3-KT: 18.3;RT4: 12.1;U-2 OS: 9.9
142,MPP4,DLG6,ENSG00000082126,Membrane palmitoylated protein 4,2,201644870-201698694,Predicted intracellular proteins,Evidence at protein level,"HPA057393, CAB079019",,Supported,Supported,Actin filaments<br>Cytosol,,Not detected,Tissue enhanced,,skin: 1.0,testis: 0.9,Cell line enhanced,,HBF TERT88: 21.5;hTEC/SVTERT24-B: 21.1;LHCN-M2: 71.6;U-87 MG: 21.4
143,MRGPRX2,MRGX2,ENSG00000183695,MAS related GPR family member X2,11,19054455-19060681,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA055220,Approved,,,,,Not detected,Tissue enhanced,,breast: 1.2;skin: 1.2,"cervix, uterine: 0.6",Not detected,,
144,MST1R,"CD136, CDw136, PTK8, RON",ENSG00000164078,Macrophage stimulating 1 receptor,3,49887002-49903873,"CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007657, HPA008180, CAB008972",Enhanced,,Approved,Cytosol,Urothelial cancer:2.33e-5 (favourable),Mixed,Tissue enhanced,,skin: 69.4,stomach: 37.2,Cell line enhanced,,CAPAN-2: 84.1;HaCaT: 46.9;HBEC3-KT: 41.5;hTCEpi: 57.4;RT4: 49.8
145,MYCL,"bHLHe38, LMYC, MYCL1",ENSG00000116990,V-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog,1,39895426-39902256,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA063132,,,Supported,Nucleus,Lung cancer:4.49e-4 (favourable),Expressed in all,Tissue enhanced,,skin: 41.6,urinary bladder: 23.7,Group enriched,7.0,U-266/70: 372.1;U-266/84: 268.8
146,NDUFA4L2,"FLJ26118, NUOMS",ENSG00000185633,"NDUFA4, mitochondrial complex associated like 2",12,57234903-57240715,Predicted membrane proteins,Evidence at protein level,HPA055323,,,Approved,Mitochondria,Renal cancer:1.37e-5 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 152.3;skin: 191.7,placenta: 104.2,Cell line enriched,8.0,AN3-CA: 123.9
147,NECTIN1,"CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12",ENSG00000110400,Nectin cell adhesion molecule 1,11,119623408-119729084,"CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB016135, HPA026846",Approved,,,,,Expressed in all,Tissue enhanced,,esophagus: 108.6;skin: 161.7,cerebral cortex: 50.3,Cell line enhanced,,HaCaT: 203.5
148,NECTIN4,"LNIR, nectin-4, PRR4, PVRL4",ENSG00000143217,Nectin cell adhesion molecule 4,1,161070995-161089599,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA010775,Enhanced,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,esophagus: 45.9;skin: 79.5,"breast,placenta: 17.1",Cell line enhanced,,BEWO: 53.8;HaCaT: 32.5;SK-BR-3: 35.3;T-47d: 28.8
149,NHLH2,"bHLHa34, HEN2, NSCL2",ENSG00000177551,Nescient helix-loop-helix 2,1,115836377-115843917,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055238,Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,,Not detected,Tissue enhanced,,skin: 3.9,"cerebral cortex,testis: 0.8",Cell line enriched,11.0,SCLC-21H: 68.8
150,NIPAL1,"DKFZp686A06115, NPAL1",ENSG00000163293,NIPA like domain containing 1,4,47914142-48040173,Predicted membrane proteins,Evidence at transcript level,HPA036765,Uncertain,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,esophagus: 24.0;skin: 30.8,rectum: 14.6,Cell line enhanced,,A-431: 11.6;HaCaT: 13.6;RT4: 14.3
151,NIPAL4,ICHYN,ENSG00000172548,NIPA like domain containing 4,5,157460019-157474717,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038259,Approved,,,,Urothelial cancer:6.82e-4 (favourable),Tissue enhanced,Tissue enhanced,,skin: 41.9,esophagus: 10.2,Group enriched,10.0,hTCEpi: 21.3;RT4: 80.1
152,NKD2,Naked2,ENSG00000145506,Naked cuticle homolog 2,5,1008829-1038943,Predicted intracellular proteins,Evidence at protein level,HPA049463,Uncertain,,,,"Renal cancer:2.66e-5 (unfavourable), Melanoma:9.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,lung: 5.5;skin: 3.8,spleen: 2.9,Cell line enhanced,,BEWO: 17.2;NB-4: 11.0;RPMI-8226: 29.0
153,NSG1,,ENSG00000168824,Neuron-specific protein family member 1 ,4,4348140-4419058,Predicted membrane proteins,Evidence at protein level,HPA035775,,,Approved,Mitochondria,Pancreatic cancer:9.49e-4 (favourable),Tissue enhanced,Tissue enhanced,,skin: 143.1,cerebral cortex: 68.6,Group enriched,8.0,HAP1: 87.0;SCLC-21H: 199.6;SH-SY5Y: 87.5;SK-MEL-30: 63.7;TIME: 166.8;U-698: 51.3
154,NTF4,"GLC1O, NT-4/5, NTF5",ENSG00000225950,Neurotrophin 4,19,49061066-49065054,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA049376,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,skin: 36.6,prostate: 11.4,Cell line enhanced,,CAPAN-2: 12.1;HaCaT: 27.5;hTCEpi: 36.4
155,NXPH4,NPH4,ENSG00000182379,Neurexophilin 4,12,57216795-57226449,Predicted secreted proteins,Evidence at transcript level,,,,,,"Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 8.3;prostate: 7.1;skin: 12.2,placenta: 3.8,Cell line enhanced,,AN3-CA: 71.1;RH-30: 60.3
156,OCA2,"BEY, BEY1, BEY2, D15S12, EYCL, EYCL2, EYCL3, P",ENSG00000104044,OCA2 melanosomal transmembrane protein,15,27754875-28099358,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,skin: 7.4;thyroid gland: 5.8,testis: 2.5,Group enriched,6.0,SH-SY5Y: 6.3;SK-MEL-30: 18.3
157,OLFM2,"NOE2, OlfC",ENSG00000105088,Olfactomedin 2,19,9853718-9936552,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA049961, HPA057771",Uncertain,,Approved,Nucleoplasm,"Renal cancer:2.21e-4 (unfavourable), Colorectal cancer:3.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 124.0;skin: 111.2,adipose tissue: 36.8,Cell line enhanced,,AN3-CA: 23.7;SH-SY5Y: 25.7;U-2 OS: 30.2;WM-115: 25.2
158,OTX1,,ENSG00000115507,Orthodenticle homeobox 1,2,63050057-63057836,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB012341, HPA052122",Approved,,Uncertain,Nuclear speckles<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 1.7;skin: 6.1,prostate: 1.0,Cell line enriched,6.0,THP-1: 35.9
159,OVOL1,HOVO1,ENSG00000172818,Ovo like transcriptional repressor 1,11,65787022-65797219,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003984,Uncertain,,Approved,Nucleus,"Renal cancer:1.00e-13 (favourable), Endometrial cancer:1.87e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 37.3;skin: 33.4;testis: 35.3,urinary bladder: 15.5,Cell line enhanced,,A-431: 16.3;BEWO: 49.5;HaCaT: 27.3;RT4: 24.5;SK-BR-3: 17.8
160,PARD6G,"PAR-6G, PAR6gamma",ENSG00000178184,Par-6 family cell polarity regulator gamma,18,80157232-80247546,Predicted intracellular proteins,Evidence at protein level,HPA047017,Uncertain,,Approved,Plasma membrane,Liver cancer:3.19e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 44.9,thyroid gland: 30.0,Cell line enhanced,,HMC-1: 31.8;U-2 OS: 30.2
161,PCOTH,C1QTNF9B-AS1,ENSG00000205861,Pro-X-Gly collagen triple helix like repeat containing,13,23888889-23897263,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,prostate: 24.5;skin: 25.5;testis: 38.3,epididymis: 6.1,Cell line enhanced,,hTEC/SVTERT24-B: 11.5;LHCN-M2: 10.9
162,PHYHIP,"DYRK1AP3, KIAA0273, PAHX-AP",ENSG00000168490,Phytanoyl-CoA 2-hydroxylase interacting protein,8,22219704-22232341,Predicted intracellular proteins,Evidence at protein level,"HPA068030, HPA069318",Approved,,Enhanced,Mitochondria,,Mixed,Tissue enhanced,,cerebral cortex: 182.7;skin: 58.2,adrenal gland: 28.8,Cell line enhanced,,RPMI-8226: 6.4;SH-SY5Y: 3.6
163,PKP3,,ENSG00000184363,Plakophilin 3,11,392614-404908,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012993, HPA062937",Enhanced,,Enhanced,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 98.2;skin: 148.2,duodenum: 31.4,Cell line enhanced,,A-431: 131.6;HaCaT: 174.9;SK-BR-3: 111.1
164,PLA2G3,GIII-SPLA2,ENSG00000100078,Phospholipase A2 group III,22,31134809-31140607,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA021016,Uncertain,,,,Head and neck cancer:4.47e-4 (favourable),Mixed,Tissue enhanced,,esophagus: 4.4;lung: 3.6;skin: 10.2,parathyroid gland: 1.5,Group enriched,6.0,AF22: 14.3;AN3-CA: 13.6;NTERA-2: 7.5;SCLC-21H: 13.2
165,PLA2G4B,"cPLA2-beta, HsT16992",ENSG00000243708,Phospholipase A2 group IVB,15,41837775-41848147,"Enzymes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,skin: 36.3,esophagus: 14.1,Cell line enhanced,,RT4: 5.9
166,PLCH2,"KIAA0450, PLC-eta2, PLCeta2, PLCL4, RP3-395M20.1",ENSG00000149527,Phospholipase C eta 2,1,2425980-2505530,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA072705,Approved,,,,,Mixed,Tissue enhanced,,skin: 58.5,esophagus: 14.0,Cell line enhanced,,HBEC3-KT: 91.6;hTCEpi: 42.6;hTERT-HME1: 26.9
167,PLEKHG5,"GEF720, KIAA0720, Syx, Tech",ENSG00000171680,Pleckstrin homology and RhoGEF domain containing G5,1,6466092-6520061,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049570,Uncertain,,Approved,Nucleus,Glioma:8.72e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 110.9,spleen: 34.6,Mixed,,
168,PNLIPRP3,,ENSG00000203837,Pancreatic lipase related protein 3,10,116427867-116477957,"Enzymes, Predicted secreted proteins",Evidence at transcript level,"HPA046202, HPA052009",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,breast: 12.0;skin: 5.4,esophagus: 1.8,Cell line enriched,14.0,hTCEpi: 233.8
169,POF1B,"FLJ22792, POF",ENSG00000124429,"Premature ovarian failure, 1B",X,85277396-85379743,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA002033, HPA050027",Approved,,Supported,Nucleoplasm<br>Golgi apparatus,"Liver cancer:2.03e-4 (unfavourable), Endometrial cancer:3.08e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,skin: 144.4,rectum: 52.8,Cell line enhanced,,A549: 19.6;CAPAN-2: 19.5;HaCaT: 19.9;RT4: 60.9
170,PPP1R13L,"IASPP, RAI",ENSG00000104881,Protein phosphatase 1 regulatory subunit 13 like,19,45379634-45406349,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB005016, HPA041231, HPA059883",Approved,,Enhanced,Cytosol,"Lung cancer:3.39e-5 (unfavourable), Ovarian cancer:5.40e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 191.4,esophagus: 53.8,Cell line enhanced,,hTCEpi: 138.6
171,PPP1R14C,"CPI17-like, KEPI, NY-BR-81",ENSG00000198729,Protein phosphatase 1 regulatory inhibitor subunit 14C,6,150143076-150250357,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 76.2;thyroid gland: 101.5,heart muscle: 52.5,Cell line enhanced,,HBEC3-KT: 63.9;hTCEpi: 77.1
172,PROM2,,ENSG00000155066,Prominin 2,2,95274453-95291308,Predicted membrane proteins,Evidence at protein level,"CAB046005, HPA063728",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane<br>Cell Junctions,"Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 71.1,esophagus: 44.6,Cell line enhanced,,A-431: 69.3;CAPAN-2: 119.5;HaCaT: 65.0;hTCEpi: 56.7;RT4: 66.9;SK-BR-3: 88.2
173,PRR33,"C11orf89, LOC728008",ENSG00000283787,Proline rich 33,11,1888577-1891895,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,skin: 12.2,"skeletal muscle,spleen: 11.5",Cell line enhanced,,Daudi: 2.2;HDLM-2: 8.1;Karpas-707: 4.1;U-937: 3.4
174,PRRX2,"PMX2, PRX2",ENSG00000167157,Paired related homeobox 2,9,129665641-129722674,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA006607, HPA026808",Approved,,Approved,Nucleoplasm<br>Nuclear bodies,,Mixed,Tissue enhanced,,"cervix, uterine: 9.9;skin: 10.7",testis: 6.3,Cell line enhanced,,BJ: 24.1;BJ hTERT+: 16.5;fHDF/TERT166: 32.1;U-2197: 31.5
175,PRSS53,POL3S,ENSG00000151006,"Protease, serine 53",16,31083425-31089628,"Enzymes, Predicted secreted proteins",Evidence at transcript level,"HPA034955, HPA034956",Uncertain,,,,,Mixed,Tissue enhanced,,skin: 1.1,prostate: 0.5,Cell line enhanced,,SCLC-21H: 5.5
176,PSG7,,ENSG00000221878,Pregnancy specific beta-1-glycoprotein 7 (gene/pseudogene),19,42924132-42937178,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA046327,Approved,,,,,Not detected,Tissue enhanced,,placenta: 5.8;skin: 1.4,smooth muscle: 0.9,Cell line enhanced,,BJ: 1.3;HBF TERT88: 2.2;U-2197: 1.7
177,PTGS1,"COX1, PGHS-1, PTGHS",ENSG00000095303,Prostaglandin-endoperoxide synthase 1,9,122370530-122395703,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA002834, CAB020315",Enhanced,,Supported,Golgi apparatus<br>Vesicles,"Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 161.6,fallopian tube: 86.1,Cell line enhanced,,ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
178,PTK6,BRK,ENSG00000101213,Protein tyrosine kinase 6,20,63528001-63537370,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB032952, HPA036070, HPA036071",Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 61.0;skin: 60.4,duodenum: 29.2,Cell line enhanced,,A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
179,RAB38,NY-MEL-1,ENSG00000123892,"RAB38, member RAS oncogene family",11,88113242-88175467,Predicted intracellular proteins,Evidence at protein level,HPA071701,,,Uncertain,Nuclear bodies<br>Mitochondria,Renal cancer:8.26e-4 (favourable),Expressed in all,Tissue enhanced,,skin: 47.4,esophagus: 36.3,Cell line enhanced,,hTCEpi: 216.3;hTERT-HME1: 203.2;SK-MEL-30: 129.2
180,RAB3D,"D2-2, GOV, RAB16, RAD3D",ENSG00000105514,"RAB3D, member RAS oncogene family",19,11322046-11346270,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB018067, HPA063283",Approved,,Approved,Vesicles,Glioma:3.30e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 62.5,esophagus: 28.1,Cell line enhanced,,SK-BR-3: 51.2
181,RAB7B,"MGC16212, MGC9726",ENSG00000276600,"RAB7B, member RAS oncogene family",1,205976740-206003461,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:4.87e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 59.9,gallbladder: 22.9,Cell line enhanced,,HBEC3-KT: 23.4;HMC-1: 75.9;hTCEpi: 26.8
182,RAET1E,"bA350J20.7, LETAL, ULBP4",ENSG00000164520,Retinoic acid early transcript 1E,6,149883375-149898102,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054022,,,Approved,Focal adhesion sites<br>Cytosol,,Tissue enhanced,Tissue enhanced,,esophagus: 70.8;skin: 29.0,tonsil: 10.3,Cell line enhanced,,HBEC3-KT: 15.9;HeLa: 20.3;hTCEpi: 15.6;SiHa: 11.2;U-87 MG: 9.0
183,RAPGEFL1,Link-GEFII,ENSG00000108352,Rap guanine nucleotide exchange factor like 1,17,40177010-40195656,Predicted intracellular proteins,Evidence at protein level,HPA022895,,,Approved,Nucleus<br>Microtubules<br>Cytokinetic bridge,"Renal cancer:0.00e+0 (unfavourable), Cervical cancer:3.28e-4 (favourable), Breast cancer:8.43e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 277.1,esophagus: 93.2,Expressed in all,,
184,RARG,"NR1B3, RARC",ENSG00000172819,Retinoic acid receptor gamma,12,53210567-53232980,"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA053883,Supported,,Supported,Nucleoplasm,"Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 143.4,esophagus: 77.3,Mixed,,
185,RDH12,"FLJ30273, LCA13, RP53, SDR7C2",ENSG00000139988,Retinol dehydrogenase 12 (all-trans/9-cis/11-cis),14,67701886-67734452,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,gallbladder: 27.7;skin: 58.2,kidney: 13.6,Not detected,,
186,RHOV,"ARHV, Chp, WRCH2",ENSG00000104140,Ras homolog family member V,15,40872214-40874289,Predicted intracellular proteins,Evidence at protein level,HPA053343,Enhanced,,,,"Lung cancer:2.33e-4 (unfavourable), Pancreatic cancer:4.19e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 71.5;skin: 72.6,tonsil: 20.2,Cell line enhanced,,HaCaT: 66.2;SK-BR-3: 237.1
187,RIN1,,ENSG00000174791,Ras and Rab interactor 1,11,66330242-66336840,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA035491,Uncertain,,Approved,Nucleus<br>Nuclear membrane,"Renal cancer:9.34e-7 (unfavourable), Endometrial cancer:2.21e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 19.3,cerebral cortex: 5.2,Cell line enhanced,,U-2197: 58.9
188,RNASE7,RAE1,ENSG00000165799,Ribonuclease A family member 7,14,21042226-21044234,Predicted secreted proteins,Evidence at protein level,"HPA005690, CAB062560, CAB068225",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 72.0;skin: 29.2;tonsil: 19.6,gallbladder: 11.1,Cell line enhanced,,HBEC3-KT: 17.9;hTCEpi: 7.6;hTERT-HME1: 40.4
189,RNF225,,ENSG00000269855,Ring finger protein 225,19,58396090-58397079,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,esophagus: 2.0;skin: 1.7,prostate: 0.6,Not detected,,
190,RNF39,"HZFw1, LIRF",ENSG00000204618,Ring finger protein 39,6,30070266-30075887,Predicted intracellular proteins,Evidence at protein level,"CAB019278, HPA047115",Uncertain,,Uncertain,Vesicles<br>Plasma membrane<br>Centrosome,,Mixed,Tissue enhanced,,skin: 3.5,breast: 2.0,Cell line enhanced,,A-431: 1.1;U-266/84: 2.5
191,RP11-566K11.2,,ENSG00000198211,,16,89919165-89936092,Predicted membrane proteins,Evidence at protein level,"CAB011512, HPA043640, HPA046280",Uncertain,,,,,Not detected,Tissue enhanced,,skin: 1.0,testis: 0.6,Cell line enriched,7.0,SK-MEL-30: 12.4
192,RP13-210D15.9,,ENSG00000283644,,X,135309480-135309659,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,seminal vesicle: 1.1;skin: 1.4,thyroid gland: 0.6,Not detected,,
193,RP4-816N1.8,,ENSG00000283297,Uncharacterized protein ENSP00000372125 ,12,2849039-2857083,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,skin: 4.3;testis: 7.4,"appendix,lymph node,spleen: 1.3",Cell line enhanced,,HeLa: 1.5;Karpas-707: 2.1
194,S100A3,S100E,ENSG00000188015,S100 calcium binding protein A3,1,153547329-153549372,Predicted intracellular proteins,Evidence at protein level,"HPA042674, HPA056140",Approved,,Enhanced,Nucleoli<br>Cytosol,Renal cancer:1.61e-6 (unfavourable),Expressed in all,Tissue enhanced,,lung: 19.9;skin: 17.3,esophagus: 7.5,Cell line enhanced,,A549: 71.3;U-2197: 41.8
195,S100A5,S100D,ENSG00000196420,S100 calcium binding protein A5,1,153537147-153541765,Predicted intracellular proteins,Evidence at protein level,HPA064184,,,Approved,Nucleoplasm,,Group enriched,Tissue enhanced,,skin: 4.3;thyroid gland: 8.8,lymph node: 1.7,Cell line enhanced,,RT4: 15.9;SCLC-21H: 20.4
196,S1PR5,"Edg-8, EDG8",ENSG00000180739,Sphingosine-1-phosphate receptor 5,19,10512742-10517931,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029683,Enhanced,,,,Renal cancer:6.71e-7 (unfavourable),Group enriched,Tissue enhanced,,cerebral cortex: 14.9;skin: 22.1,spleen: 12.0,Cell line enhanced,,HaCaT: 25.0;RT4: 14.8;T-47d: 10.9;U-2 OS: 10.7
197,SAPCD1,"C6orf26, NG23",ENSG00000228727,Suppressor APC domain containing 1,6,31762799-31764851,Predicted intracellular proteins,Evidence at transcript level,HPA071699,,,Approved,Vesicles<br>Cell Junctions,,Mixed,Tissue enhanced,,skin: 3.2,bone marrow: 1.0,Cell line enhanced,,HeLa: 2.5
198,SCEL,"FLJ21667, MGC22531",ENSG00000136155,Sciellin,13,77535674-77645263,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039737, HPA040154",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.73e-5 (unfavourable), Pancreatic cancer:1.24e-4 (unfavourable), Endometrial cancer:4.07e-4 (unfavourable), Renal cancer:6.87e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 476.6;skin: 397.0,lung: 98.9,Cell line enhanced,,CAPAN-2: 28.9;HaCaT: 54.8;HBEC3-KT: 21.3;RPTEC TERT1: 89.6
199,SDC1,"CD138, SDC, SYND1, syndecan",ENSG00000115884,Syndecan 1,2,20200797-20225433,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB002424, HPA006185",Approved,,Supported,Focal adhesion sites,"Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 250.7;skin: 287.9,liver: 144.7,Cell line enhanced,,U-266/84: 739.8
200,SDR9C7,"RDHS, SDR-O",ENSG00000170426,Short chain dehydrogenase/reductase family 9C member 7,12,56923154-56934405,Predicted intracellular proteins,Evidence at protein level,HPA039059,,,Approved,Nucleoli<br>Cytosol,,Group enriched,Tissue enhanced,,esophagus: 10.7;skin: 46.1,tonsil: 6.8,Not detected,,
201,SERPINB7,MEGSIN,ENSG00000166396,Serpin family B member 7,18,63752935-63805376,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA024200,Enhanced,,Approved,Endoplasmic reticulum<br>Mitochondria,Pancreatic cancer:3.03e-5 (unfavourable),Mixed,Tissue enhanced,,skin: 123.7;tonsil: 34.1,breast: 17.4,Cell line enhanced,,BJ: 202.3;fHDF/TERT166: 131.6;HaCaT: 363.6;HBF TERT88: 215.1;U-138 MG: 215.5
202,SERPINE3,,ENSG00000253309,Serpin family E member 3,13,51335773-51364735,Predicted secreted proteins,Evidence at protein level,"HPA051904, HPA055804",Uncertain,,,,,Not detected,Tissue enhanced,,skin: 1.0,small intestine: 0.8,Not detected,,
203,SH3RF2,"FLJ23654, Hepp1, POSHER, PPP1R39, RNF158",ENSG00000156463,SH3 domain containing ring finger 2,5,145936579-146081791,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035903, HPA058119",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,skin: 67.3,heart muscle: 26.1,Cell line enhanced,,CACO-2: 57.4
204,SLC10A6,SOAT,ENSG00000145283,Solute carrier family 10 member 6,4,86823468-86849263,Predicted membrane proteins,Evidence at protein level,HPA016662,Enhanced,,,,,Group enriched,Tissue enhanced,,esophagus: 11.0;skin: 17.3,adipose tissue: 6.2,Cell line enhanced,,BJ: 1.4;BJ hTERT+: 1.0;HaCaT: 1.1
205,SLC28A3,CNT3,ENSG00000197506,Solute carrier family 28 member 3,9,84275457-84340683,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA023311, HPA024729",Approved,,,,Breast cancer:3.37e-4 (favourable),Mixed,Tissue enhanced,,breast: 10.7;gallbladder: 11.7;skin: 9.8,bone marrow: 6.2,Cell line enriched,8.0,HMC-1: 51.9
206,SLC44A5,"CTL5, MGC34032",ENSG00000137968,Solute carrier family 44 member 5,1,75202131-75611116,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA047455, HPA051011",Uncertain,,Approved,Cytosol,Renal cancer:6.52e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 12.6,parathyroid gland: 8.1,Cell line enhanced,,SH-SY5Y: 12.2;TIME: 11.9
207,SLC45A2,"AIM-1, MATP, OCA4",ENSG00000164175,Solute carrier family 45 member 2,5,33944616-33984730,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,skin: 1.2;testis: 1.2,"prostate,rectum: 0.3",Cell line enriched,43.0,SK-MEL-30: 48.5
208,SLC6A11,GAT3,ENSG00000132164,Solute carrier family 6 member 11,3,10816200-10940733,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA037981,Supported,Supported,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 18.1;skin: 6.7,esophagus: 5.5,Cell line enhanced,,HaCaT: 11.8;Hep G2: 10.7;hTCEpi: 8.5;NTERA-2: 6.6
209,SLC6A2,"NAT1, NET, NET1, SLC6A5",ENSG00000103546,Solute carrier family 6 member 2,16,55655604-55706192,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004057, HPA076311, CAB078195",Enhanced,Supported,Approved,Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enhanced,,adrenal gland: 29.2;placenta: 18.4;skin: 15.7,testis: 11.4,Cell line enriched,35.0,SH-SY5Y: 519.4
210,SLC6A9,GLYT1,ENSG00000196517,Solute carrier family 6 member 9,1,43991500-44031467,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA013977,Uncertain,,Approved,Nucleus<br>Golgi apparatus,"Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 49.7,adrenal gland: 30.8,Cell line enhanced,,hTCEpi: 77.6
211,SOX15,"SOX20, SOX26, SOX27",ENSG00000129194,SRY-box 15,17,7588178-7590170,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA067196, HPA074049",Enhanced,,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Vesicles,,Tissue enhanced,Tissue enhanced,,skin: 40.5,esophagus: 17.5,Group enriched,8.0,A-431: 108.6;HaCaT: 120.2;HBEC3-KT: 39.0;hTCEpi: 38.2
212,SPTBN2,SCA5,ENSG00000173898,"Spectrin beta, non-erythrocytic 2",11,66685248-66729226,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009844, HPA039293, HPA043529",Enhanced,,Supported,Cell Junctions<br>Cytosol,Pancreatic cancer:3.14e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 73.0;skin: 59.3;testis: 48.4,parathyroid gland: 24.6,Cell line enhanced,,NTERA-2: 49.7;SCLC-21H: 59.4
213,SPTSSB,"ADMP, C3orf57, ssSPTb",ENSG00000196542,Serine palmitoyltransferase small subunit B,3,161344792-161372880,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA047712,,,Approved,Nuclear speckles,,Tissue enhanced,Tissue enhanced,,skin: 48.3;stomach: 59.4;urinary bladder: 36.3,prostate: 23.4,Group enriched,9.0,MCF7: 892.8;RT4: 244.7
214,SRY,TDF,ENSG00000184895,Sex determining region Y,Y,2786855-2787699,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 1.0;testis: 2.8,esophagus: 0.7,Cell line enhanced,,RT4: 1.7
215,ST6GALNAC2,"SIAT7, SIAT7B, SIATL1, ST6GalNAII, STHM",ENSG00000070731,"ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2",17,76565379-76586956,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048849,Uncertain,,,,Pancreatic cancer:6.48e-4 (unfavourable),Expressed in all,Tissue enhanced,,fallopian tube: 68.6;skin: 50.8,testis: 38.9,Cell line enhanced,,BEWO: 20.9;HaCaT: 23.9;hTCEpi: 48.8;MCF7: 20.9;SK-MEL-30: 70.3
216,SULT2B1,HSST2,ENSG00000088002,Sulfotransferase family 2B member 1,19,48552075-48599425,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB033013, HPA041724, HPA043539",Approved,,Supported,Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,esophagus: 152.2;skin: 152.4,"cervix, uterine: 45.8",Cell line enhanced,,CAPAN-2: 59.3;MCF7: 32.5;T-47d: 31.4
217,TAC4,"HK-1, PPT-C, Pptc",ENSG00000176358,Tachykinin 4 (hemokinin),17,49838309-49848017,Predicted secreted proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 2.0,liver: 1.0,Cell line enhanced,,A549: 2.3;BEWO: 5.7;CACO-2: 2.9
218,TAS2R5,T2R5,ENSG00000127366,Taste 2 receptor member 5,7,141790217-141791367,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 5.0,epididymis: 3.4,Cell line enhanced,,hTCEpi: 3.8
219,TBC1D3B,"PRC17, TBC1D3I",ENSG00000274808,TBC1 domain family member 3B,17,36165681-36176636,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,skin: 6.3;testis: 6.0,spleen: 2.9,Cell line enhanced,,CAPAN-2: 7.5;T-47d: 5.6
220,TFAP2A,"AP-2, AP2TF, TFAP2",ENSG00000137203,Transcription factor AP-2 alpha,6,10393186-10419659,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000326, HPA028850, HPA056871",Enhanced,,Enhanced,Nucleoplasm,Lung cancer:1.09e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,breast: 40.0;placenta: 42.3;skin: 76.1,epididymis: 24.9,Cell line enhanced,,HDLM-2: 103.3
221,TFAP2C,"AP2-GAMMA, ERF1, hAP-2g, TFAP2G",ENSG00000087510,Transcription factor AP-2 gamma,20,56629302-56639283,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB016061, CAB016079, HPA055179, HPA057076",Enhanced,,Supported,Nucleoplasm,Cervical cancer:6.90e-4 (favourable),Tissue enhanced,Tissue enhanced,,skin: 63.0,breast: 31.6,Cell line enhanced,,BEWO: 183.4;MCF7: 128.7;SK-BR-3: 231.1;WM-115: 112.9
222,TFAP2E,AP2E,ENSG00000116819,Transcription factor AP-2 epsilon,1,35573370-35595328,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,skin: 7.2,lymph node: 2.1,Cell line enhanced,,NB-4: 4.5;U-937: 4.6
223,TMEM154,FLJ32028,ENSG00000170006,Transmembrane protein 154,4,152618632-152680165,Predicted membrane proteins,Evidence at protein level,"HPA019184, HPA055411",Uncertain,,Approved,Nucleoplasm<br>Nuclear membrane,,Mixed,Tissue enhanced,,esophagus: 64.3;skin: 69.5,tonsil: 24.1,Cell line enhanced,,HMC-1: 62.0
224,TMEM184A,"MGC9712, SDMG1",ENSG00000164855,Transmembrane protein 184A,7,1542235-1560821,Predicted membrane proteins,Evidence at protein level,"HPA053790, HPA071312",Uncertain,,Approved,Nucleoplasm,"Colorectal cancer:1.12e-4 (unfavourable), Thyroid cancer:9.94e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 33.5,esophagus: 26.5,Cell line enhanced,,SCLC-21H: 43.0;SK-BR-3: 42.7;T-47d: 47.5
225,TMPRSS13,"MSPL, TMPRSS11",ENSG00000137747,"Transmembrane protease, serine 13",11,117900643-117929459,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 36.4,"cervix, uterine,esophagus: 10.5",Cell line enhanced,,BEWO: 32.1;MCF7: 22.3;SK-BR-3: 36.2;T-47d: 46.4
226,TNFRSF18,"AITR, CD357, GITR",ENSG00000186891,TNF receptor superfamily member 18,1,1203508-1206691,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA008025,Approved,,,,"Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 43.3,parathyroid gland: 18.0,Group enriched,11.0,RPMI-8226: 148.8;SCLC-21H: 173.4
227,TNFRSF19,"TAJ, TAJ-alpha, TRADE, TROY",ENSG00000127863,TNF receptor superfamily member 19,13,23570370-23676104,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA010135,,,Approved,Nucleoplasm<br>Mitochondria,"Renal cancer:9.13e-7 (favourable), Lung cancer:3.87e-4 (favourable)",Expressed in all,Tissue enhanced,,skin: 128.9,fallopian tube: 50.5,Cell line enhanced,,BJ hTERT+: 65.9;fHDF/TERT166: 48.4;Hep G2: 58.9;SK-MEL-30: 111.1;WM-115: 86.3
228,TNFRSF25,"APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR",ENSG00000215788,TNF receptor superfamily member 25,1,6461151-6466195,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA069834,,,Approved,Nucleus<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites,"Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 29.6,spleen: 12.1,Cell line enhanced,,HDLM-2: 24.6;RPMI-8226: 17.9
229,TNS4,CTEN,ENSG00000131746,Tensin 4,17,40475828-40501597,Predicted intracellular proteins,Evidence at protein level,,,,,,Lung cancer:5.16e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 66.6,esophagus: 31.6,Cell line enhanced,,HaCaT: 123.8;HBEC3-KT: 447.5;hTCEpi: 328.7;hTERT-HME1: 108.8
230,TP53AIP1,p53AIP1,ENSG00000120471,Tumor protein p53 regulated apoptosis inducing protein 1,11,128934731-128943399,Predicted intracellular proteins,Evidence at transcript level,"HPA044300, HPA048797",Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 6.3;skin: 22.2,fallopian tube: 4.1,Not detected,,
231,TP63,"EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L",ENSG00000073282,Tumor protein p63,3,189631416-189897279,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000083, HPA006288, HPA007010",Enhanced,,Enhanced,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Breast cancer:1.07e-4 (favourable),Group enriched,Tissue enhanced,,esophagus: 60.9;skin: 164.1,urinary bladder: 28.8,Group enriched,5.0,HaCaT: 77.1;HBEC3-KT: 119.9;hTCEpi: 89.8;hTERT-HME1: 90.5;RT4: 147.6
232,TRPV3,VRL3,ENSG00000167723,Transient receptor potential cation channel subfamily V member 3,17,3510502-3557995,"Disease related genes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,HPA069550,,,Approved,Plasma membrane<br>Centrosome<br>Cytosol,,Mixed,Tissue enhanced,,skin: 5.1;small intestine: 4.5,duodenum: 1.7,Cell line enhanced,,BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
233,TSPAN10,OCSP,ENSG00000182612,Tetraspanin 10,17,81637171-81648749,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,skin: 1.5,lymph node: 1.0,Cell line enhanced,,SK-MEL-30: 13.4;U-87 MG: 7.4
234,TUFT1,,ENSG00000143367,Tuftelin 1,1,151540305-151583583,Predicted intracellular proteins,Evidence at protein level,"HPA028112, HPA054301",Approved,Approved,Approved,Vesicles,Endometrial cancer:4.83e-4 (unfavourable),Expressed in all,Tissue enhanced,,skin: 92.8,esophagus: 25.8,Mixed,,
235,UGT3A2,,ENSG00000168671,UDP glycosyltransferase family 3 member A2,5,36035017-36071358,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA059475,Uncertain,,Approved,Nucleus<br>Cytosol,,Tissue enriched,Tissue enhanced,,skin: 11.9;testis: 4.6,bone marrow: 3.2,Cell line enhanced,,HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
236,UNC93A,"dJ366N23.1, dJ366N23.2",ENSG00000112494,Unc-93 homolog A (C. elegans),6,167271169-167316019,Predicted membrane proteins,Evidence at protein level,HPA035729,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 9.7;liver: 7.1;skin: 17.8,esophagus: 5.6,Group enriched,9.0,CACO-2: 6.1;Hep G2: 2.1;SCLC-21H: 3.7
237,USH1G,"ANKS4A, FLJ33924, Sans",ENSG00000182040,USH1 protein network component sans,17,74916084-74923256,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA024360,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,epididymis: 2.3;esophagus: 2.6;skin: 1.8,testis: 1.4,Cell line enhanced,,HaCaT: 1.6;hTCEpi: 1.2;K-562: 1.2;MCF7: 1.5;U-2 OS: 1.0
238,VANGL2,"KIAA1215, LPP1, LTAP, MGC119403, MGC119404, STB1, STBM, STBM1",ENSG00000162738,VANGL planar cell polarity protein 2,1,160400586-160428678,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA027043,Uncertain,,,,,Expressed in all,Tissue enhanced,,skin: 44.6,cerebral cortex: 18.1,Cell line enhanced,,AF22: 105.2;NTERA-2: 43.1;SH-SY5Y: 30.7
239,WISP3,CCN6,ENSG00000112761,WNT1 inducible signaling pathway protein 3,6,112054072-112070969,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA062438, HPA078340",,,Approved,Endoplasmic reticulum,,Mixed,Tissue enhanced,,epididymis: 3.0;skin: 2.0,fallopian tube: 1.8,Cell line enhanced,,RT4: 4.6;THP-1: 1.2;U-2197: 1.2
240,WNT10A,,ENSG00000135925,Wnt family member 10A,2,218880363-218899581,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA013898,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,skin: 8.3,placenta: 3.9,Cell line enhanced,,CAPAN-2: 36.8;HaCaT: 106.8;HDLM-2: 47.5;U-266/70: 47.5
241,WNT4,WNT-4,ENSG00000162552,Wnt family member 4,1,22117305-22143969,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011397,Uncertain,,Approved,Vesicles,"Pancreatic cancer:4.90e-4 (favourable), Melanoma:5.34e-4 (unfavourable)",Mixed,Tissue enhanced,,skin: 49.2,ovary: 15.3,Cell line enhanced,,HaCaT: 7.6;SCLC-21H: 12.2;SK-BR-3: 6.6
242,WNT7B,,ENSG00000188064,Wnt family member 7B,22,45920362-45977129,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 21.4,urinary bladder: 8.0,Cell line enhanced,,A549: 108.4;HeLa: 71.0;U-87 MG: 92.0
243,XG,PBDX,ENSG00000124343,Xg blood group,X,2752050-2815927,"Blood group antigen proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,Breast cancer:4.25e-4 (unfavourable),Mixed,Tissue enhanced,,skin: 41.1,breast: 15.4,Group enriched,6.0,ASC diff: 71.8;ASC TERT1: 49.4;fHDF/TERT166: 35.9;hTCEpi: 41.4;T-47d: 32.3
244,XKRX,"XKR2, XPLAC",ENSG00000182489,"XK related, X-linked",X,100913445-100929433,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,Thyroid cancer:3.52e-4 (favourable),Mixed,Tissue enhanced,,skin: 9.4,tonsil: 3.1,Cell line enriched,5.0,CACO-2: 6.8
245,ZNF385A,"DKFZp586G1122, Hzf, ZFP385, ZNF385",ENSG00000161642,Zinc finger protein 385A,12,54369133-54391298,Predicted intracellular proteins,Evidence at protein level,HPA039799,,,Supported,Nucleus<br>Cytosol,"Renal cancer:9.75e-5 (unfavourable), Colorectal cancer:5.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,skin: 170.0,cerebral cortex: 66.1,Cell line enhanced,,HEL: 98.3
246,ZNF750,"FLJ13841, Zfp750",ENSG00000141579,Zinc finger protein 750,17,82829435-82840578,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA021573, HPA023012",Enhanced,,,,,Mixed,Tissue enhanced,,esophagus: 60.5;skin: 54.4,salivary gland: 13.0,Cell line enhanced,,BEWO: 16.4;hTCEpi: 4.5;MCF7: 3.6;SK-BR-3: 9.5
